although
vaccin
influenza
viru
effect
method
combat
infect
clear
product
need
acceler
efficaci
improv
gener
live
attenu
human
influenza
vaccin
laiv
ration
engin
mutat
directli
genom
viru
two
laiv
base
success
laiv
anim
influenza
virus
third
candid
uniqu
nsmutant
never
use
laiv
vaccin
potenti
laiv
determin
analysi
attenu
interferon
product
immunogen
abil
protect
mice
ferret
studi
demonstr
ideal
laiv
candid
provid
import
inform
effect
differ
ns
mutat
viru
show
laiv
engin
directli
genom
emergingcircul
influenza
virus
influenza
virus
highli
contagi
human
anim
pathogen
famili
orthomyxovirida
annual
influenza
epidem
result
million
infect
caus
fatal
worldwid
influenza
viral
genom
compos
eight
neg
sens
singlestrand
rna
segment
vrna
togeth
encod
protein
influenza
viru
vaccin
updat
frequent
antigen
drift
variant
escap
antibodi
neutral
rapidli
displac
previous
circul
strain
also
need
swiftli
gener
vaccin
combat
unpredict
intermitt
influenza
viru
pandem
eg
caus
antigen
shift
virus
emerg
anim
reservoir
errorpron
rnadepend
rna
polymeras
larg
divers
viral
reservoir
frequent
interspeci
transmiss
reassort
segment
rna
genom
coinfect
power
evolutionari
mechan
make
influenza
virus
extrem
challeng
pathogen
predict
control
antivir
vaccin
uniqu
influenza
viru
respons
pandem
provid
recent
exampl
evolut
rapid
dissemin
pandem
viru
late
april
first
pandem
isol
identifi
center
diseas
control
prevent
cdc
unit
state
sequenc
analysi
indic
quadrupl
reassort
viru
genom
vrna
viru
origin
deriv
north
american
classic
swine
virus
ha
np
ns
north
american
human
virus
north
american
avian
virus
pa
eurasian
avianlik
swine
virus
na
antigen
distinct
season
viru
circul
human
sinc
reintroduct
littl
preexist
immun
human
popul
particularli
among
individu
born
thu
viru
spread
global
result
million
infect
ten
thousand
death
prior
invest
pandem
prepared
provid
increas
global
capac
product
larg
quantiti
vaccin
extraordinari
effort
mani
health
care
profession
yield
safe
fairli
effect
vaccin
fall
howev
lack
vaccin
first
winter
season
southern
hemispher
shortag
vaccin
earli
influenza
season
northern
hemispher
illustr
need
develop
method
improv
influenza
viru
vaccin
product
vaccin
approv
human
use
unit
state
food
drug
administr
either
inactiv
split
vaccin
repres
major
vaccin
current
administ
live
attenu
influenza
viru
vaccin
laiv
inactiv
vaccin
laiv
produc
creat
reassort
virus
gener
contain
six
vrna
pa
np
ns
master
donor
strain
plu
two
glycoprotein
vrna
ha
na
viru
antigen
match
strain
predict
circul
upcom
influenza
season
eg
reassort
vaccin
seed
stock
prepar
use
classic
reassort
techniqu
increasingli
use
plasmidbas
reversegenet
although
revers
genet
enhanc
abil
gener
influenza
viru
vaccin
current
laiv
inactiv
approach
requir
signific
lead
time
vaccin
product
clear
innov
strategi
need
develop
test
anim
model
present
studi
use
multiseg
revers
transcript
polymeras
chain
reaction
mrtpcr
acceler
reversegenet
technolog
rapidli
engin
interferon
ifn
induc
attenu
phenotyp
natur
gene
constel
novel
viru
protein
influenza
viru
multifunct
protein
play
import
role
viru
replic
potent
type
ifn
antagonist
mutat
andor
delet
typic
induc
stronger
ifn
respons
host
turn
suppress
replic
influenza
viru
enhanc
immun
recognit
carboxi
termin
delet
influenza
protein
success
exploit
creat
experiment
laiv
avian
equin
swine
influenza
virus
howev
ideal
nsbase
laiv
nslaiv
anim
virus
differ
delet
due
influenc
strain
specif
variat
ns
gene
viru
lineag
gene
constel
novel
reassort
protein
uniqu
properti
distinguish
protein
typic
influenza
virus
eg
lack
residu
cterminu
mutat
requir
gener
optim
nslaiv
candid
unknown
therefor
creat
panel
experiment
nslaiv
candid
differ
delet
ns
vrna
analyz
vaccin
potenti
nslaiv
vitro
vivo
identifi
best
candid
experi
infecti
viru
perform
use
procedur
facil
met
exceed
requir
set
forth
us
depart
health
human
servic
propag
influenza
virus
vitro
experi
infecti
virus
conduct
use
enhanc
biosafeti
level
laboratori
practic
procedur
describ
center
diseas
control
prevent
interim
biosafeti
guidelin
experi
involv
anim
perform
biosafeti
level
contain
laboratori
approv
use
center
diseas
control
prevent
us
depart
agricultur
anim
studi
conduct
approv
anim
care
use
protocol
wadsworth
center
nysdoh
us
center
diseas
control
prevent
anim
experi
conduct
complianc
requir
feder
state
regulatori
agenc
use
husbandri
procedur
limit
discomfort
distress
pain
injuri
human
embryon
kidney
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
madindarbi
canin
kidney
mdck
cell
human
lung
adenocarcinoma
cell
maintain
eagl
minimum
essenti
medium
emem
supplement
fb
mdck
wt
influenza
viru
anew
creat
reversegenet
directli
human
swab
specimen
collect
new
york
state
april
delet
introduc
ns
plasmid
gener
three
mutant
ns
segment
fig
nucleotid
cdna
ns
segment
replac
stop
codon
gener
nucleotid
replac
stop
codon
gener
nucleotid
delet
open
read
frame
nep
maintain
gener
recombin
virus
wt
gener
cotransfect
eight
reversegenet
plasmid
carri
cdna
gene
segment
cocultur
monolay
adapt
hoffmann
et
al
briefli
plasmid
gene
segment
mix
incub
lipofectamin
invitrogen
carlsbad
ca
min
lipofectaminedna
mixtur
transfer
confluent
cell
cocultur
tissu
cultur
dish
incub
co
transfect
supernat
replac
ml
optimem
medium
invitrogen
supplement
bsa
fraction
v
invitrogen
tpcktrypsin
worthington
lakewood
nj
antibioticantimycot
invitrogen
three
day
post
transfect
supernat
collect
virus
propag
mdck
cell
stock
viral
stock
stock
anim
studi
gener
propag
stock
multipl
infect
moi
tcid
cell
mdck
cell
titer
virus
use
studi
determin
tissu
cultur
infecti
dose
tcid
plaqu
assay
mdck
cell
tcid
assay
accur
consist
determin
titer
nsmutant
smallplaqu
phenotyp
confluent
monolay
mdck
cell
infect
moi
tcid
cell
recombin
wildtyp
wt
nslaiv
candid
triplic
one
hour
post
infect
hpi
inocula
remov
cell
wash
twice
emem
supplement
bsa
fraction
v
tpcktrypsin
antibioticantimycot
ad
supernat
collect
hpi
infect
cell
perform
similarli
except
moi
tcid
cell
use
viru
growth
medium
emem
supplement
bsa
fraction
v
tpcktrypsin
antibioticantimycot
vsvgfp
viru
mediat
bioassay
cell
inocul
one
recombin
influenza
virus
moi
tcid
cell
mockinocul
supernat
collect
hpi
supernat
treat
uvirradi
inactiv
virus
transfer
cell
follow
h
incub
supernat
remov
cell
inocul
vsvgfp
viru
moi
tcid
cell
gfp
express
cell
examin
fluoresc
microscopi
hpi
vsvgfp
rtpcr
detect
mrna
cell
inocul
variou
influenza
virus
hpi
total
rna
purifi
use
trizol
reagent
invitrogen
ng
use
templat
rtpcr
use
qiagen
onestep
rtpcr
kit
qiagen
valencia
ca
primer
gapdh
target
rtpcr
paramet
min
min
cycl
min
follow
final
extens
quantit
rtpcr
assay
mrna
ifn
stimul
gene
isg
cell
inocul
one
recombin
virus
moi
hpi
total
rna
extract
cell
use
trizol
reagent
invitrogen
total
rna
use
gener
cdna
revertaid
revers
transcriptas
fermenta
glen
burni
md
oligodt
primer
total
volum
accord
manufactur
protocol
cdna
gene
specif
primer
mix
brilliant
ii
sybr
green
qpcr
mastermix
agil
santa
clara
ca
use
templat
qpcr
total
volum
reaction
analysi
perform
lightcycl
roch
indianapoli
mrna
level
normal
rrna
level
express
fold
increas
rel
averag
level
rna
mockinocul
sampl
collect
time
point
nfold
express
valu
calcul
accord
method
three
biolog
replic
measur
technic
triplic
primer
use
analysi
viru
attenu
studi
femal
balbcj
mice
jackson
laboratori
bar
harbor
separ
microisol
cage
age
allow
acclim
laboratori
day
prior
studi
group
femal
balbcj
anesthet
isofluran
inocul
intranas
tcid
recombin
viru
pb
diluent
mock
inocul
pb
serv
control
bodi
weight
clinic
symptom
mice
monitor
daili
day
nine
mice
group
euthan
day
post
inocul
dpi
nasal
wash
micegroup
collect
insert
needl
trachea
wash
nasal
turbin
ml
viru
collect
medium
vcm
emem
supplement
bsa
fraction
v
antibioticantimycot
collect
nostril
lung
micegroup
homogen
use
mm
stainless
steel
bb
tissu
lyser
ii
qiagen
ml
vcm
viru
titrat
lung
micegroup
fix
buffer
formalin
hour
store
ethanol
day
embed
paraffin
histopatholog
examin
histopatholog
evalu
immunohistochem
ihc
assay
done
use
routin
hematoxylineosin
stain
lung
tissu
histopatholog
chang
ihc
assay
perform
section
tissu
use
monoclon
antibodi
nucleoprotein
np
influenza
viru
antibodypolym
conjug
visual
appli
ultravis
lp
system
napthol
phosphat
substrat
thermo
scientificlab
vision
tissu
section
neg
control
consist
sequenti
tissu
section
incub
isotyp
control
monoclon
antibodi
vaccin
microneutr
assay
viru
challeng
studi
group
acclimat
femal
balbcj
mice
jackson
laboratori
anesthet
isofluran
intranas
inocul
tcid
one
virus
pb
diluent
els
inocul
pb
serv
control
serum
isol
blood
sampl
obtain
mous
tail
vein
dpi
level
neutral
antibodi
present
sera
assess
microneutr
assay
briefli
serum
dilut
prior
serial
dilut
pb
mix
tcid
viru
incub
h
transfer
mdck
cell
plate
dpi
plate
stain
crystal
violet
neutral
titer
determin
dpi
mice
per
group
challeng
intranas
tcid
ld
mice
mouseadapt
variant
creat
serial
lung
passag
balbcj
mice
mouseadapt
variant
creat
intranas
inocul
weekold
balbcj
lung
harvest
day
post
inocul
homogen
clarifi
use
inocul
mice
total
seven
passag
submit
journal
virolog
diseas
symptom
weight
vaccin
mice
monitor
day
four
mice
viru
group
euthan
day
post
challeng
lung
homogen
ml
vcm
titer
determin
tcid
assay
caus
dramat
morbid
mice
anim
becam
moribund
lost
greater
start
bodi
weight
euthan
human
reason
male
fitch
ferret
tripl
f
farm
sayr
pa
month
age
serolog
neg
hemagglutin
inhibit
hi
assay
current
circul
influenza
virus
use
studi
ferret
hous
durat
experi
duoflow
bioclean
mobil
clean
room
lab
product
inc
seaford
de
group
ferret
inocul
intranas
tcid
one
virus
wt
ferret
monitor
clinic
sign
dpi
previous
describ
nasal
wash
collect
dpi
titrat
mdck
cell
tcid
assay
serum
isol
blood
collect
week
immunizationinfect
use
neutral
assay
ferret
challeng
pfu
week
postimmun
monitor
clinic
sign
diseas
dpi
nasal
wash
collect
dpi
titrat
mdck
cell
plaqu
assay
creat
four
recombin
virus
fig
deriv
anew
york
directli
origin
clinic
specimen
use
mrtpcr
genom
amplif
clone
techniqu
laiv
candid
design
produc
ctermin
truncat
protein
respect
retain
ntermin
amino
acid
fig
ctermin
truncat
select
base
upon
success
prior
studi
use
laboratoryadapt
viru
anim
virus
candid
engin
infram
delet
nucleotid
affect
residu
nep
residu
protein
fig
mutat
never
use
creat
laiv
design
analog
delet
occur
natur
viru
isol
pig
delet
attenu
normal
highli
pathogen
viru
chicken
thu
panel
virus
creat
consist
wt
three
nslaiv
compos
entir
vrna
confirm
desir
mutat
present
panel
virus
rescu
reversegenet
use
mrtpcr
amplifi
genom
viru
analyz
amplicon
agaros
gel
electrophoresi
fig
fig
ns
vrna
recombin
virus
subsequ
confirm
sequenc
mrtpcr
amplicon
data
shown
replic
kinet
recombin
nslaiv
candid
compar
kinet
recombin
wt
viru
madin
darbi
canin
kidney
mdck
cell
cultur
fig
wt
viru
replic
rapidli
reach
highest
titer
tcid
ml
h
replic
kinet
similar
wt
viru
mdck
cell
also
achiev
high
titer
tcid
ml
h
fig
virus
show
delay
replic
rate
compar
wt
rate
fig
h
howev
eventu
reach
peak
titer
similar
wt
viru
tcid
ml
fig
nslaiv
candid
show
pronounc
attenu
reduct
compar
wt
human
lung
epitheli
cell
line
statist
signific
p
time
point
examin
fig
result
indic
nslaiv
attenu
human
lung
epitheli
cell
propag
effici
mdck
cell
vsvgfp
viru
mediat
ifn
bioassay
use
determin
whether
nslaiv
candid
induc
elev
level
type
ifn
rel
induct
wt
viru
human
cell
inocul
one
recombin
influenza
virus
mockinocul
multipl
infect
moi
use
ensur
effici
infect
cell
regardless
rel
replic
kinet
nslaiv
cell
line
supernat
cell
mockinocul
influenza
viru
nt
inhibit
gfp
express
vsvgfp
viru
indic
present
high
level
supernat
fig
contrast
supernat
cell
infect
inhibit
gfp
express
earli
hpi
fig
supernat
infect
cell
contain
lower
level
ifn
sinc
gfp
express
vsvgfp
inhibit
supernat
harvest
hpi
fig
supernat
cell
infect
wt
viru
nt
show
inhibit
gfp
express
hpi
fig
vsvgfp
bioassay
result
verifi
rtpcr
amplif
mrna
cell
inocul
wt
viru
one
nslaiv
candid
hpi
nslaiv
candid
induc
high
level
mrna
product
wherea
wt
induc
low
level
mrna
mockinocul
cell
detect
mrna
fig
quantit
rtpcr
qrtpcr
use
investig
product
mrna
type
iii
ifn
ifnstimul
gene
isg
cell
compar
mockinocul
cell
wt
viru
infect
induc
increas
mrna
hpi
nslaiv
candid
induc
increas
fig
qrtpcr
analysi
type
iii
ifn
mrna
indic
nslaiv
candid
induc
increas
mrna
hpi
wherea
wt
viru
show
increas
fig
although
wt
viru
induc
increas
chemokin
vaccin
candid
induc
increas
mrna
fig
isg
mx
import
host
resist
influenza
virus
product
human
mxa
block
wt
virusinfect
cell
contrast
induct
mxa
mrna
observ
cell
infect
anyon
nslaiv
candid
hpi
fig
qrtpcr
data
fig
correl
result
ifn
bioassay
fig
attenu
nslaiv
candid
seen
human
lung
cell
line
fig
nevertheless
qrtpcr
result
help
delin
differ
host
respons
variou
nslaiv
consist
induc
greatest
host
antivir
respons
induct
ifn
isg
mrna
lag
behind
induct
nslaiv
fig
hpi
consider
greater
wt
viru
mice
also
use
examin
level
attenu
nslaiv
candid
vivo
mice
inocul
intranas
tcid
wt
virus
mockinocul
clinic
sign
diseas
ruffl
fur
observ
mice
inocul
wt
viru
earli
day
post
inocul
dpi
data
shown
weight
loss
becam
evid
dpi
mice
recov
dpi
fig
contrast
mice
inocul
one
vaccin
candid
show
clinic
sign
diseas
continu
gain
weight
rate
mockinocul
mice
fig
student
ttest
show
weight
loss
caus
wt
viru
statist
differ
nslaiv
day
p
viral
titer
lung
infect
mice
approxim
lower
titer
wt
virusinfect
mice
time
point
analyz
dpi
fig
titer
wt
viru
significantli
higher
nslaiv
dpi
p
student
ttest
notabl
laiv
clear
mous
lung
rapidli
averag
titer
approxim
lower
titer
wt
viru
dpi
respect
fig
although
averag
tcid
lung
mice
infect
wt
viru
day
pi
averag
titer
limit
detect
nslaiv
candid
also
show
lower
titer
upper
respiratori
tract
fig
differ
observ
titer
wt
viru
nslaiv
upper
respiratori
tract
also
statist
signific
exampl
comparison
titer
wt
student
ttest
show
significantli
differ
p
time
point
examin
fig
nevertheless
vaccin
candid
detect
dpi
fig
could
promot
strong
adapt
immun
respons
histopatholog
analysi
lung
mice
euthan
dpi
show
lesion
typic
influenza
viru
infect
sever
histopatholog
observ
mice
inocul
recombin
wt
nslaiv
directli
correl
amount
viru
present
anim
lung
mice
inocul
wt
viru
sever
patholog
chang
mice
inocul
show
least
sever
patholog
begin
dpi
epitheli
necrosi
slough
bronchiol
evid
wt
infect
mice
data
shown
peribronchiolar
interstiti
inflamm
also
evid
dpi
wt
infect
mice
data
shown
immunohistochemistri
lung
tissu
collect
dpi
mice
inocul
wt
viru
nslaiv
indic
viral
np
present
nuclei
cytoplasm
infect
cell
red
stain
includ
epitheli
cell
bronchiol
arrow
pneumocyt
either
detach
line
alveoli
fig
number
antigen
posit
cell
vari
depend
viru
strain
correspond
extent
histopatholog
observ
amount
viru
present
lung
compar
fig
intriguingli
viru
antigen
detect
lobe
lung
mice
inocul
recombin
virus
except
mice
inocul
dpi
np
antigen
posit
cell
depict
fig
infrequ
detect
mice
infect
group
mice
inocul
intranas
tcid
nslaiv
candid
either
control
wt
mock
microneutr
assay
demonstr
vaccin
candid
elicit
neutral
antibodi
nslaiv
immun
mice
averag
antibodi
titer
group
rang
dpi
fig
mice
challeng
lethal
mouseadapt
variant
dpi
nslaiv
candid
prior
infect
wt
viru
protect
mice
challeng
diseas
symptom
observ
mice
immun
nslaiv
candid
wt
control
contrast
diseas
symptom
includ
ruffl
fur
hunch
postur
weight
loss
observ
mockimmun
mice
earli
day
post
challeng
dpc
symptom
progress
sever
diseas
anim
show
statist
signific
p
student
ttest
weight
loss
compar
wt
nslaiv
immun
mice
fig
mice
becam
moribund
succumb
infect
dpc
high
titer
viru
also
present
mockimmun
mice
dpc
tcid
ml
dpc
tcid
ml
fig
contrast
viru
detect
lung
mice
immun
wt
control
dpc
fig
mous
challeng
data
demonstr
nslaiv
candid
includ
highli
attenu
induc
steril
immun
challeng
lethal
variant
ferret
well
establish
anim
model
gener
recapitul
sever
outcom
diseas
observ
human
infect
influenza
viru
assess
attenu
nslaiv
candid
inocul
group
ferret
intranas
tcid
vaccin
candid
wt
viru
titer
virus
recov
nasal
wash
rang
tcid
ml
day
wt
virusinfect
group
nslaiv
attenu
variou
degre
fig
rel
wt
nslaiv
show
least
reduct
titer
dpi
fig
laiv
least
attenu
ferret
fig
similar
observ
mice
rel
wt
viru
laiv
show
reduct
titer
laiv
limit
detect
least
reduct
dpi
fig
diseas
symptom
weight
also
monitor
dpi
ferret
group
includ
anim
inocul
wt
viru
remain
alert
play
durat
observ
period
clinic
symptom
sustain
fever
sneez
nasal
discharg
diarrhea
gastrointestin
symptom
consist
observ
infect
anim
infect
wt
viru
caus
modest
weight
loss
ferret
fig
student
ttest
show
wt
infect
caus
weight
loss
significantli
differ
everi
time
point
post
infect
compar
infect
laiv
p
wt
weight
loss
also
significantli
differ
dpi
dpi
compar
weight
loss
caus
significantli
differ
dpi
compar
weight
chang
infect
anim
p
fig
sera
blood
collect
week
immunizationinfect
analyz
presenc
neutral
antibodi
fig
nslaiv
candid
induc
strong
neutral
antibodi
respons
similar
titer
elicit
wt
viru
infect
fig
viru
neutral
data
illustr
although
laiv
highli
attenu
readili
clear
host
nevertheless
induc
potenti
protect
antibodi
respons
determin
whether
nslaiv
candid
protect
ferret
infect
homosubtyp
viru
challeng
ferret
week
post
immun
pfu
viru
isol
femal
patient
sever
respiratori
diseas
littl
diseas
weight
loss
observ
ferret
ferret
immun
infect
wt
viru
nslaiv
candid
nt
show
diseas
symptom
weight
loss
data
shown
contrast
high
titer
viru
detect
ferret
dpc
nslaiv
immun
ferret
low
level
nasal
wash
dpc
fig
ferret
immun
nslaiv
lower
viral
titer
anim
fig
summari
nslaiv
candid
dramat
inhibit
initi
replic
viru
stringent
challeng
condit
pfu
vaccin
anim
rapidli
clear
infect
limit
detect
dpc
studi
demonstr
recombin
nslaiv
creat
directli
human
swab
materi
effect
experiment
vaccin
virus
vitro
nslaiv
candid
replic
effici
canin
mdck
cell
produc
type
ifn
lack
isg
mx
effici
replic
mdck
cell
import
practic
implic
approv
cell
line
product
influenza
viru
vaccin
importantli
pronounc
attenu
observ
human
lung
epitheli
cell
line
correl
induct
type
ifn
isg
nslaiv
consist
previou
studi
show
influenza
virus
delet
truncat
protein
attenu
ifncompet
cell
result
ifn
bioassay
rtpcr
analysi
show
host
innat
immun
respons
induc
much
higher
level
human
lung
epitheli
cell
infect
infect
wt
viru
data
also
indic
like
strong
induc
ifn
isg
human
primat
stimul
innat
immun
system
major
advantag
nslaiv
strategi
act
natur
adjuv
enhanc
adapt
immun
respons
host
mice
immun
nslaiv
asymptomat
tissu
titer
virus
dramat
lower
titer
wt
viru
indic
significantli
attenu
vivo
histopatholog
immunohistochem
analysi
also
show
nslaiv
sever
attenu
rapidli
clear
mice
lesion
lung
smallest
sporad
mice
inocul
correl
level
viru
replic
observ
nslaiv
candid
although
highli
attenu
gener
complet
immun
protect
lethal
challeng
mouseadapt
variant
examin
nslaiv
ferret
substanti
pronounc
attenu
phenotyp
candid
observ
mice
exampl
laiv
sever
attenu
rapidli
clear
two
host
fig
fig
although
laiv
candid
markedli
attenu
ferret
elicit
strong
neutral
antibodi
respons
dramat
inhibit
replic
face
hightit
challeng
result
rapid
clearanc
challeng
viru
dpc
collect
data
vitro
vivo
mice
ferret
studi
show
least
attenu
laiv
candid
attenu
laiv
new
type
nslaiv
subtl
infram
delet
nt
affect
residu
nep
residu
laiv
design
analog
natur
attenu
variant
normal
highli
pathogen
viru
delet
residu
shown
reduc
bind
host
cleavag
polyadenyl
specif
factor
cpsf
reduc
protein
stabil
enhanc
type
ifn
respons
viru
data
prove
delet
ns
vrna
quadrupl
reassort
viru
also
stimul
host
innat
immun
respons
specif
mxa
attenu
viru
fact
attenu
two
distantli
relat
influenza
virus
suggest
region
ns
gene
protein
good
target
nslaiv
mani
divers
influenza
virus
potenti
develop
antivir
compound
role
delet
residu
nep
elucid
induct
ifn
isg
similar
slightli
lower
induct
suggest
nep
mutat
may
also
attenu
effect
warrant
futur
investig
laiv
safeti
potenti
problem
associ
reassort
laiv
circul
influenza
virus
also
paramount
import
challeng
experiment
approach
describ
studi
current
licens
laiv
six
internalprotein
encod
vrna
deriv
coldadapt
temperatur
sensit
ann
master
donor
strain
ca
viru
origin
isol
subject
mani
serial
passag
vitro
licens
vaccin
mani
point
mutat
multipl
vrna
eg
np
attenu
viru
enhanc
safeti
inhibit
rapid
gener
revert
andor
singlegen
reassort
lost
attenu
temperatur
sensit
phenotyp
contain
wildtyp
ha
na
vrna
although
nsdelet
use
studi
larg
enough
rapid
revers
wildtyp
phenotyp
via
point
mutat
highli
unlik
substitut
ns
vrna
segment
via
reassort
either
wildtyp
virus
season
virus
would
remov
singl
attenu
vrna
seriou
concern
particularli
situat
emerg
strain
pandem
potenti
yet
becom
widespread
therefor
envis
swap
cisact
segmentspecif
packag
signal
vrna
segment
ha
ns
recent
effect
order
prevent
reassort
enhanc
safeti
futur
nsbase
laiv
addit
anim
studi
human
trial
specif
nslaiv
recent
studi
wacheck
et
al
need
help
defin
safeti
paramet
nslaiv
human
drawback
use
internalprotein
encod
vrna
ca
cytotox
lymphocyt
epitop
present
influenza
viru
mutat
host
immun
pressur
reduc
immun
recognit
intern
protein
express
current
circul
strain
addit
mani
immun
evad
amino
acid
substitut
present
novel
reassort
like
viru
emerg
anim
reservoir
strategi
accomplish
equal
greater
speed
typic
reversegenet
base
vaccin
approach
often
requir
viru
isol
prior
rtpcr
amplif
ha
na
specif
primer
importantli
laiv
approach
outlin
studi
advantag
stimul
host
innat
adapt
immun
system
entir
repertoir
protein
express
circul
new
emerg
strain
summari
rapidli
gener
panel
recombin
laiv
directli
patient
specimen
introduc
attenu
mutat
ns
gene
emerg
pandem
influenza
viru
result
demonstr
two
delet
mutat
ns
vrna
uniqu
gene
constel
viru
attenu
viru
human
lung
epitheli
cell
line
mice
ferret
new
type
nslaiv
design
shown
highli
attenu
elicit
strong
innat
adapt
immun
respons
result
protect
mice
subsequ
challeng
lethal
mouseadapt
variant
ferret
challeng
creation
laiv
ration
introduct
attenu
mutat
genom
emerg
current
circul
strain
influenza
viru
could
integr
current
futur
vaccin
product
scheme
import
potenti
advantag
reassortantbas
vaccin
seed
stock
product
strategi
current
use
weekold
femal
balbcj
mice
inocul
intranas
tcid
wt
nslaiv
mock
inocul
bodi
weight
inocul
mice
record
daili
repres
percent
anim
weight
day
inocul
day
b
viral
titer
lung
homogen
inocul
mice
determin
mous
tcid
assay
dpi
c
viral
titer
nasal
airway
inocul
mice
averag
group
shown
error
bar
determin
sem
limit
detect
viru
titrat
indic
dot
line
b
c
